Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04566978 · ClinicalTrials.gov registry record · Early Phase 1
89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)
A Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT04566978: Completed Early Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04566978 is a Early Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04566978, a Early Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main purposes of this study include: Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767 Finding the best dose amount of 89Zr-DFO-REGN3767 Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767
Interventions
- DIAGNOSTIC_TEST PET/CT
- DRUG 89Zr-DFO-REGN3767
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2025-03-21 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04566978
The ClinicalTrials.gov registry entry for NCT04566978 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PET/CT is the first listed.
NCT04566978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04566978 about?
NCT04566978 is a clinical study titled "89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL)". The main purposes of this study include: Looking at the way the body absorbs, distributes, and gets rid of 89Zr-DFO-REGN3767 Finding the best dose amount of 89Zr-DFO-REGN3767 Finding the best time for PET scanning after injection of 89Zr-DFO-REGN3767
What is the current status of trial NCT04566978?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2020-09-11. Estimated completion is 2025-03-21.
What interventions are being tested in trial NCT04566978?
The interventions under investigation include: PET/CT (DIAGNOSTIC_TEST), 89Zr-DFO-REGN3767 (DRUG).
Who is sponsoring clinical trial NCT04566978?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.